Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

135 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial.
Lieverse RIY, Van Limbergen EJ, Oberije CJG, Troost EGC, Hadrup SR, Dingemans AC, Hendriks LEL, Eckert F, Hiley C, Dooms C, Lievens Y, de Jong MC, Bussink J, Geets X, Valentini V, Elia G, Neri D, Billiet C, Abdollahi A, Pasquier D, Boisselier P, Yaromina A, De Ruysscher D, Dubois LJ, Lambin P. Lieverse RIY, et al. Among authors: dooms c. BMC Cancer. 2020 Jun 15;20(1):557. doi: 10.1186/s12885-020-07055-1. BMC Cancer. 2020. PMID: 32539805 Free PMC article.
Influence of cisplatin-use, age, performance status and duration of chemotherapy on symptom control in advanced non-small cell lung cancer: detailed symptom analysis of a randomised study comparing cisplatin-vindesine to gemcitabine.
Vansteenkiste J, Vandebroek J, Nackaerts K, Dooms C, Galdermans D, Bosquée L, Delobbe A, Deschepper K, Van Kerckhoven W, Vandeurzen K, Deman R, D'Odemont JP, Siemons L, Van den Brande P, Dams N; Leuven Lung Cancer Group. Vansteenkiste J, et al. Among authors: dooms c. Lung Cancer. 2003 May;40(2):191-9. doi: 10.1016/s0169-5002(02)00515-9. Lung Cancer. 2003. PMID: 12711121 Review.
Long-term survival of surgically staged IIIA-N2 non-small-cell lung cancer treated with surgical combined modality approach: analysis of a 7-year prospective experience.
Lorent N, De Leyn P, Lievens Y, Verbeken E, Nackaerts K, Dooms C, Van Raemdonck D, Anrys B, Vansteenkiste J; Leuven Lung Cancer Group. Lorent N, et al. Among authors: dooms c. Ann Oncol. 2004 Nov;15(11):1645-53. doi: 10.1093/annonc/mdh435. Ann Oncol. 2004. PMID: 15520066 Clinical Trial.
135 results